Prentice Capital Management, LP Zynerba Pharmaceuticals, Inc. Transaction History

Prentice Capital Management, LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 12, 2021	SELL	$3.27 - $4.64 $1.28 Million - $1.81 Million	-390,381 Closed	0 $0
Q3 2020 Nov 16, 2020	SELL	$3.23 - $4.3 $124,338 - $165,528	-38,495 Reduced 8.98%	390,381 $1.29 Million
Q2 2020 Aug 14, 2020	BUY	$3.31 - $6.54 $289,426 - $571,857	87,440 Added 25.61%	428,876 $1.45 Million
Q1 2020 May 15, 2020	BUY	$2.9 - $6.16 $382,278 - $812,011	131,820 Added 62.89%	341,436 $1.31 Million
Q4 2019 Feb 14, 2020	BUY	$5.61 - $8.57 $1.18 Million - $1.8 Million	209,616 New	209,616 $1.27 Million

774K

Ticker ZYNE
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 45,753,100
Description
Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It is developing Zygel, a pharmaceutically-produced cannabidiol formulated as a permeation-enhanced gel for t...

Get notified when there are updates to the investment portfolio of Prentice Capital Management, LP, based on Form 13F filings with the SEC.

Stay updated on Prentice Capital Management, LP with notifications on news.